Centre National De La Recherche Scientifique

Institut De Recherche Pour Le Developpement

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Sorbonne Université

Université Paris—sud

Université Paris-Sud 11

Institut Du Cerveau Et De La Moelle Epiniere

Nls Pharmaceutics Ag

Université Paris-Saclay

Nls Pharma Ag

Bruno Figadere

Fanny Schmidt

Rita Raisman-Vozari

Alain Fournet

Xavier Franck

Laurent Ferrie

Pierre Champy

Eric Konofal

Reynald Hocquemiller

Rodolphe Baudoin

Patrick Michel

Mohamed Fakhfakh

Philippe Loiseau

Eric Prina

Julia Sepulveda

Sylvia Rita Vozari

Nashira Campos Vieira

Gael Le Douaron

Blandine Seon Meniel

Gaël Le Douaron

Joël Vacus

Clémence Rose

Patrick Pierre Michel

The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said compounds, and to the pharmaceutical compositions containing same.

1, 4, 8-triazaphenanthrene derivatives for the treatment of neurodegenerative disorders

The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.

Phacetoperane for treating of attention deficit hyperactivity disorder

The present invention relates to compounds of formula (I) below: for which: &#x2014;X represents a hydrogen atom, a halogen atom, a group NOor NH, &#x2014;Rrepresents H or &#x2014;CH&#x2014;C&#x2261;CH, and &#x2014;Rand Reach represent, independently of one another, a hydrogen atom; a saturated or unsaturated, linear or branched hydrocarbon-based chain comprising from 1 to 10 carbon atoms; or an optionally substituted aryl group, and also the pharmaceutically acceptable salts thereof, the stereoisomers thereof or mixtures of stereoisomers thereof in any proportion, in particular for use thereof as a medicament, in particular in the treatment or prevention of neurodegenerative diseases, and also the processes for the preparation thereof and the pharmaceutical compositions comprising same. 

Aminoquinoxaline derivatives for treatment of neurodegenerative diseases

The invention relates to a compound of the following formula (I), 

Indole derivatives for treating neurodegenerative diseases

The present invention relates to compounds of Formula (I) below, to their pharmaceutically acceptable salts and to their isomers or mixtures of isomers: HetAr&#x2014;X&#x2014;CHRR(I) in which: &#x2014;HetAr represents a group chosen from: &#x2014;X represents a linear, saturated or unsaturated, hydrocarbon-based chain comprising from 8 to 22 carbon atoms, optionally interrupted by an &#x2014;NH&#x2014; or &#x2014;NH&#x2014;CO&#x2014; group, &#x2014;Rrepresents a hydrogen atom or an &#x2014;OH, &#x2014;O(C-C)alkyl, &#x2014;OCO((C-C)alkyl), &#x2014;OSO((C-C)alkyl) or &#x2014;OSOH group, and &#x2014;Rrepresents a hydrogen atom or a (C-C)alkynyl, (C-C)alkenyl or (C-C)cycloalkyl group. The present invention also relates to a process for preparing the compounds of Formula (I), and also to the use thereof, especially in the treatment of neurodegenerative diseases. 

Quinoline or quinoxaline derivatives for treating neurodegenerative diseases

The invention relates to salts of 2-substituted quinolines, the manufacturing method for same, and use of the same for the production of drugs. Said salts are advantageous in that the same can be obtained in crystalline form, which facilitates their implementation in the manufacture of pharmaceutical compositions.

Salts of 2-substituted quinolines

The invention relates to the use of quinolines having general formula (I), wherein Rdenotes H; alkyl C-C; alkenyl or alkynyl C-C; &#x2014;CHO; heteroaryl; alkyl C-Cor alkenyl or alkynyl C-Ccomprising at least one substituent selected from among O, halogen, &#x2014;OH, &#x2014;CHO, &#x2014;COOH, aryloxycarbonyl, alkyloxycarbonyl C-C, alkenyloxycarbonyl C-C, nitrile, aryl, heteroaryl, arylsulphone, alkylsulphone C-C, thioalkyl or aminoalkyl C-C; alkenyl C-Cbearing at least one substituent selected from among NH, aleoxy C-C, phenoxy, cycloakyl C-Cor heteroaryloxy, alkenyl or alkynyl C-Ccomprising at least one trialkylsilyl C-C; R, in position 3, 6 or 8, denotes H; halogen; &#x2014;OH; &#x2014;CHO; &#x2014;COOH; alkyl or aleoxy C-C; &#x2014;NH2; alkenyl C-C; or alkynyl C-C; Rand Rdo not both denote H. The invention is used for the preparation of a medicine to treat protozoan and retrovirus co-infections 

Substituted quinolines for the treatment of protozoa and retrovirus co-infections

Growing community of inventors

Saint Cheron, France

Bruno Figadere